公开(公告)号：US20240342172A1

公开(公告)日：2024-10-17

申请号：US17314550

申请日：2021-05-07

申请人： VIRACTA THERAPEUTICS, INC. ,  TRUSTEES OF BOSTON UNIVERSITY

发明人： Ronald J. Berenson ,  Douglas V. Faller

IPC分类号： A61K31/506 ,  A61K9/00 ,  A61K31/165 ,  A61K31/167 ,  A61K31/18 ,  A61K31/19 ,  A61K31/27 ,  A61K31/4045 ,  A61K31/4402 ,  A61K31/473 ,  A61K31/513 ,  A61K31/52 ,  A61K31/522 ,  A61K38/12 ,  A61K38/15 ,  A61K45/06

CPC分类号： A61K31/506 ,  A61K9/0053 ,  A61K31/165 ,  A61K31/167 ,  A61K31/18 ,  A61K31/19 ,  A61K31/27 ,  A61K31/4045 ,  A61K31/4402 ,  A61K31/473 ,  A61K31/513 ,  A61K31/52 ,  A61K31/522 ,  A61K38/12 ,  A61K38/15 ,  A61K45/06 ,  Y02A50/30

摘要： Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.

公开(公告)号：US20240342147A1

公开(公告)日：2024-10-17

申请号：US18659819

申请日：2024-05-09

申请人： Bonafide Health, LLC

发明人： Deanna J. Nelson ,  James R. Komorowski

IPC分类号： A61K31/4402 ,  A61K9/28 ,  A61K33/06

CPC分类号： A61K31/4402 ,  A61K9/28 ,  A61K33/06 ,  A61K9/2846

摘要： The present application relates to magnesium picolinate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable magnesium to mammals and treating or preventing symptoms of magnesium deficiency.

公开(公告)号：US20240335401A1

公开(公告)日：2024-10-10

申请号：US18572752

申请日：2022-06-23

申请人： SYNAPTIVE THERAPEUTICS LLC

发明人： Matthew Halpert

IPC分类号： A61K31/137 ,  A61K31/133 ,  A61K31/145 ,  A61K31/15 ,  A61K31/343 ,  A61K31/357 ,  A61K31/402 ,  A61K31/4402 ,  A61K31/4458 ,  A61K31/451 ,  A61K31/5375 ,  A61P29/00

CPC分类号： A61K31/137 ,  A61K31/133 ,  A61K31/145 ,  A61K31/15 ,  A61K31/343 ,  A61K31/357 ,  A61K31/402 ,  A61K31/4402 ,  A61K31/4458 ,  A61K31/451 ,  A61K31/5375 ,  A61P29/00

摘要： Compositions comprising a substituted phenethylamine and methods of using the compositions for treating an inflammatory or neurological disorder in a subject in need thereof are disclosed. The substituted phenethylamine can be used at sub-hallucinogenic concentrations.

公开(公告)号：US12110263B2

公开(公告)日：2024-10-08

申请号：US17740260

申请日：2022-05-09

申请人： CORTEXYME, INC.

发明人： Andrei W. Konradi ,  Robert A. Galemmo, Jr. ,  Stephen S. Dominy ,  Casey C. Lynch ,  Leslie J. Holsinger

IPC分类号： C07C233/62 ,  A61K31/165 ,  A61K31/167 ,  A61K31/41 ,  A61K31/42 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/505 ,  A61K31/513 ,  A61K31/655 ,  A61K45/06 ,  A61P25/00 ,  A61P31/04 ,  C07B59/00 ,  C07C233/78 ,  C07C235/10 ,  C07C235/50 ,  C07C237/42 ,  C07C245/08 ,  C07C247/16 ,  C07C247/18 ,  C07C317/28 ,  C07C323/40 ,  C07C323/42 ,  C07C381/00 ,  C07D213/65 ,  C07D213/68 ,  C07D213/70 ,  C07D213/81 ,  C07D213/82 ,  C07D239/34 ,  C07D239/36 ,  C07D239/38 ,  C07D257/04 ,  C07D261/12 ,  C07D401/12 ,  C07D413/12 ,  C07F5/02

CPC分类号： C07C233/62 ,  A61K31/165 ,  A61K31/167 ,  A61K31/41 ,  A61K31/42 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/505 ,  A61K31/513 ,  A61K31/655 ,  A61K45/06 ,  A61P25/00 ,  A61P31/04 ,  C07B59/001 ,  C07C233/78 ,  C07C235/10 ,  C07C235/50 ,  C07C237/42 ,  C07C245/08 ,  C07C247/16 ,  C07C247/18 ,  C07C317/28 ,  C07C323/40 ,  C07C323/42 ,  C07C381/00 ,  C07D213/65 ,  C07D213/68 ,  C07D213/70 ,  C07D213/81 ,  C07D213/82 ,  C07D239/34 ,  C07D239/36 ,  C07D239/38 ,  C07D257/04 ,  C07D261/12 ,  C07D401/12 ,  C07D413/12 ,  C07F5/02 ,  C07C2601/08

摘要： The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.

公开(公告)号：US20240316016A1

公开(公告)日：2024-09-26

申请号：US18670632

申请日：2024-05-21

申请人： Alto Neuroscience, Inc.

发明人： Amit ETKIN ,  Wei WU ,  Chao WANG ,  Nicholas COOPER ,  Joshua JORDAN ,  Adam SAVITZ

IPC分类号： A61K31/4402 ,  A61K9/00 ,  A61K45/06 ,  A61P25/28

CPC分类号： A61K31/4402 ,  A61K9/0053 ,  A61K45/06 ,  A61P25/28

摘要： This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

公开(公告)号：US20240307406A1

公开(公告)日：2024-09-19

申请号：US18263402

申请日：2022-01-28

申请人： ADVANCED BIODESIGN

发明人： Mileidys PEREZ ,  Guillaume MARTIN

IPC分类号： A61K31/5375 ,  A61K31/265 ,  A61K31/40 ,  A61K31/4402 ,  A61K31/4409 ,  A61K45/06 ,  A61P35/00 ,  A61P37/04

CPC分类号： A61K31/5375 ,  A61K31/265 ,  A61K31/40 ,  A61K31/4402 ,  A61K31/4409 ,  A61K45/06 ,  A61P35/00 ,  A61P37/04

摘要： The present invention relates to aminothiolesters compounds for use for modulating the immune response in a subject. In particular, said compounds are comprised in a lipidic nanocapsule. The invention further relates to a pharmaceutical composition and to combination products comprising at least one aminothiolester compound and an immune checkpoint inhibitor, and their use for the treatment of cancer.

公开(公告)号：US12091409B2

公开(公告)日：2024-09-17

申请号：US17350183

申请日：2021-06-17

申请人： ASTEX THERAPEUTICS LIMITED

发明人： Anthony William James Cooper ,  Nicole Cathleen Goodwin ,  Charlotte Mary Griffiths-Jones ,  Thomas Daniel Heightman ,  Jeffrey K. Kerns ,  Hendrika Maria Gerarda Willems ,  Hongxing Yan

IPC分类号： C07D249/04 ,  A61K31/4192 ,  A61K31/4402 ,  A61K31/55 ,  A61K31/553 ,  A61K31/554 ,  A61P9/04 ,  A61P11/00 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  C07D419/12 ,  C07D419/14 ,  C07D471/04 ,  C07D498/04 ,  C07D513/04

CPC分类号： C07D419/12 ,  C07D249/04 ,  C07D401/12 ,  C07D419/14 ,  C07D498/04 ,  C07D513/04

摘要： The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof:

公开(公告)号：US12083119B2

公开(公告)日：2024-09-10

申请号：US17545217

申请日：2021-12-08

申请人： VIRACTA SUBSIDIARY, INC. ,  TRUSTEES OF BOSTON UNIVERSITY

发明人： Ronald J. Berenson ,  Douglas V. Faller

IPC分类号： A61K31/506 ,  A61K9/00 ,  A61K31/165 ,  A61K31/167 ,  A61K31/18 ,  A61K31/19 ,  A61K31/27 ,  A61K31/4045 ,  A61K31/4402 ,  A61K31/473 ,  A61K31/513 ,  A61K31/52 ,  A61K31/522 ,  A61K38/12 ,  A61K38/15 ,  A61K45/06

CPC分类号： A61K31/506 ,  A61K9/0053 ,  A61K31/165 ,  A61K31/167 ,  A61K31/18 ,  A61K31/19 ,  A61K31/27 ,  A61K31/4045 ,  A61K31/4402 ,  A61K31/473 ,  A61K31/513 ,  A61K31/52 ,  A61K31/522 ,  A61K38/12 ,  A61K38/15 ,  A61K45/06 ,  Y02A50/30 ,  A61K31/167 ,  A61K2300/00 ,  A61K31/19 ,  A61K2300/00 ,  A61K31/27 ,  A61K2300/00 ,  A61K31/4045 ,  A61K2300/00 ,  A61K31/506 ,  A61K2300/00 ,  A61K31/513 ,  A61K2300/00 ,  A61K38/12 ,  A61K2300/00

摘要： Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.

公开(公告)号：US12023348B2

公开(公告)日：2024-07-02

申请号：US15569407

申请日：2016-04-26

申请人： The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center

发明人： Ofer Sarig ,  Eli Sprecher

IPC分类号： A61K31/704 ,  A61K31/122 ,  A61K31/137 ,  A61K31/167 ,  A61K31/277 ,  A61K31/365 ,  A61K31/366 ,  A61K31/37 ,  A61K31/404 ,  A61K31/423 ,  A61K31/427 ,  A61K31/433 ,  A61K31/4402 ,  A61K31/4453 ,  A61K31/4535 ,  A61K31/454 ,  A61K31/4738 ,  A61K31/4741 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/498 ,  A61K31/53 ,  A61K31/538 ,  A61K31/5415 ,  A61K31/566 ,  A61K31/58 ,  A61K31/688 ,  A61K45/06 ,  A61P17/00 ,  A61P17/06

CPC分类号： A61K31/704 ,  A61K31/122 ,  A61K31/137 ,  A61K31/167 ,  A61K31/277 ,  A61K31/365 ,  A61K31/366 ,  A61K31/37 ,  A61K31/404 ,  A61K31/423 ,  A61K31/427 ,  A61K31/433 ,  A61K31/4402 ,  A61K31/4453 ,  A61K31/4535 ,  A61K31/454 ,  A61K31/4738 ,  A61K31/4741 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/498 ,  A61K31/53 ,  A61K31/538 ,  A61K31/5415 ,  A61K31/566 ,  A61K31/58 ,  A61K31/688 ,  A61K45/06 ,  A61P17/00 ,  A61P17/06

摘要： A method of treating an inflammation or a hyperproliferative disease in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:



a compound represented by Formula I:








or a pharmaceutically acceptable salt thereof,



a compound represented by Formula II:










and a compound represented by Formula III:








wherein the variables in Formulae I, II and III are as defined in the specification.

公开(公告)号：US20240165039A1

公开(公告)日：2024-05-23

申请号：US18421298

申请日：2024-01-24

申请人： Bayer Healthcare LLC

发明人： Javier ZUMETA PEREZ ,  Blanca ALVAREZ MALUENDA ,  Maria Pilar SANZ SAIZ ,  Maria Elena IGLESIAS PIÑEIRO ,  Anthony BELL ,  Reinhard WALTER

IPC分类号： A61K9/48 ,  A61K31/09 ,  A61K31/137 ,  A61K31/167 ,  A61K31/4402 ,  A61K31/485

CPC分类号： A61K9/4825 ,  A61K9/4866 ,  A61K9/4883 ,  A61K31/09 ,  A61K31/137 ,  A61K31/167 ,  A61K31/4402 ,  A61K31/485

摘要： The present disclosure provides for suspension-based pharmaceutical formulations for cold and flu medications, specifically suspension formulations and soft gel capsule dosage forms having reduced size. The present disclosure also provides methods of preparing the suspensions and soft gel capsule dosage forms.